Congress Materials – Society of Urologic Oncology (SUO 2024)
2024 Society of Urologic Oncology | Dec 4-6 | Dallas, TX
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
MoonRISe-1: Phase 3 Study of TAR-210 Erdafitinib Intravesical Targeted Releasing System, Versus Intravesical Chemotherapy in Patients With FGFR-Altered Intermediate-Risk Non-Muscle-Invasive Bladder Cancer
Roger Li, Gautam Jayram, Angela Girvin, Anne O’Hagan, Sabine D. Brookman-May, Jiao Song, Nicole Stone, Cateau Van Oevelen, Jose M. Calderon, Lauren Crow, Neil Beeharry, Spyros Triantos, Benjamin Pradere
Outcomes and Healthcare Resource Utilization of Patients Receiving Definitive versus Non-Definitive Treatment for Muscle-Invasive Bladder Cancer: A Real-World Analysis Within the Veteran Affairs System
Renning Zheng, Sanjay Das, Jaruda Ithisuphalap, Bolan Linghu, Kirk A. Keegan, Raymond Harvey, Eleanor O. Caplan, Sydney McIntire, Joshua Parrish, Claire Trustram Eve, Amanda M. De Hoedt, Stephen J. Freedland, Hussein Sweiti, Joel Greshock, Stephen B. Williams, Anirban P. Mitra
Penelope: Tissue Penetration of Gemcitabine Phosphate Metabolites Following TAR-200 Administration vs Standard Intravesical Installation in Mini Pigs
Siamak Daneshmand, Koen Wuyts, Marc De Meulder, Liesbeth Vereyken, Marjolein van Heerden, Herman Borghys, Geert Mannens, Karen Daniel, Samuel Spigelman
Safety and Tolerability of TAR-200 Monotherapy in Patients With Bacillus Calmette-Guérin (BCG)-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (HR NMIBC) in SunRISE-1
Siamak Daneshmand, Daniel Zainfeld, Christopher Pieczonka, Giuseppe Simone, Michiel S. van der Heijden, Martin Bögemann, David S. Morris, Philipp Spiegelhalder, Laurence H. Belkoff, Karel Decaestecker, Harm Arentsen, Shalaka Hampras, Christopher J. Cutie, Hussein Sweiti, Katharine Stromberg, Jason Martin, Abhijit Shukla, Joseph M. Jacob, Evanguelos Xylinas
SunRISe-5: A Phase 3, Randomized, Open-Label Study of TAR-200 Compared With Intravesical Chemotherapy After Bacillus Calmette-Guérin in Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer
Sima Porten, Sumeet Bhanvadia, Saltanat Najmi, Hussein Sweiti, John Maffeo, Kate Stromberg, Jovita Gale, Benjamin Pradere
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.